5th Swedish Medicinal Chemistry Symposium
The organisers invite you to participate in the 5th Swedish Medicinal Chemistry Symposium, Sweden’s premier biennial Medicinal Chemistry and Drug Discovery event focusing on recent advances in Swedish drug discovery research in academia and in industry.
At the Symposium, the Swedish Pharmaceutical Society 2026 Medicinal Chemistry prize-winner will be announced. The prize recognizes outstanding contributions to the areas of Medicinal Chemistry and Drug Discovery in Sweden.
Stay tuned for program updates! Registration will open during autumn.
Welcome to join us in Stockholm in April!
Who will attend?
This conference targets academic and industrial scientists engaged in all aspects of drug discovery and drug development. It aims to showcase the most recent trends in Drug Discovery presented by leading Swedish scientists. The meeting provides an excellent forum for networking with colleagues active in the field.
Sponsor possibilities
Gold sponsor
Fee: SEK 40.000 excl VAT
Benefits
• Exhibition stand with space for one roll-up
• 1 free registration
Exposure
• Special thanks in the opening speech
• Acknowledgement and website link with logo on symposium website
• Acknowledgement in final program
Silver sponsor
Fee: SEK 20.000 excl VAT
Exposure
• Special thanks in the opening speech
• Acknowledgement and website link with logo on symposium website
• Acknowledgement in final program
Participation fee & Scholarship
The fee for Industry delegates is SEK 6 000 and for Academy delegates SEK 4000. All fees are excl. VAT. For registration made after March 6 another SEK 1000 will be added to the fee.
Apply for scholarship for participation latest by October 31, more information and application here https://www.apotekarsocieteten.se/en/scholarships-and-prizes/
(include 25% VAT in your application for scholarship)
Time & Place
22-23 April 2026 in central Stockholm.
Program Committee
Dr Peter Sjö, Drugs for Neglected Diseases initiative (DNDi)
Dr Katarina Färnegårdh, Eirino
Prof Ulf Nilsson, Lund University
Dr Lena Ripa, AstraZeneca